Affinity Asset Advisors LLC Buys New Position in HilleVax, Inc. (NASDAQ:HLVX)

Affinity Asset Advisors LLC purchased a new position in shares of HilleVax, Inc. (NASDAQ:HLVX) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 265,859 shares of the company’s stock, valued at approximately $3,844,000.

A number of other institutional investors also recently made changes to their positions in HLVX. EntryPoint Capital LLC acquired a new stake in HilleVax in the first quarter worth approximately $80,000. Tidal Investments LLC acquired a new stake in shares of HilleVax in the first quarter valued at $207,000. Swiss National Bank raised its position in HilleVax by 22.4% in the fourth quarter. Swiss National Bank now owns 38,200 shares of the company’s stock worth $613,000 after acquiring an additional 7,000 shares in the last quarter. Rhumbline Advisers lifted its holdings in HilleVax by 27.0% in the 2nd quarter. Rhumbline Advisers now owns 42,658 shares of the company’s stock valued at $617,000 after acquiring an additional 9,073 shares during the last quarter. Finally, TD Asset Management Inc boosted its position in shares of HilleVax by 53.9% during the 2nd quarter. TD Asset Management Inc now owns 54,236 shares of the company’s stock valued at $784,000 after purchasing an additional 19,000 shares in the last quarter. 86.42% of the stock is owned by institutional investors and hedge funds.

HilleVax Price Performance

Shares of HilleVax stock opened at $1.80 on Wednesday. HilleVax, Inc. has a 12 month low of $1.55 and a 12 month high of $20.22. The business has a fifty day simple moving average of $1.80 and a 200-day simple moving average of $9.29.

HilleVax (NASDAQ:HLVX) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.83) EPS for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.10). As a group, equities research analysts expect that HilleVax, Inc. will post -2.47 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently weighed in on HLVX. Stifel Nicolaus cut shares of HilleVax from a “buy” rating to a “hold” rating and reduced their target price for the stock from $34.00 to $3.00 in a report on Tuesday, July 9th. Leerink Partners lowered HilleVax from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $28.00 to $2.00 in a research report on Tuesday, July 9th. Leerink Partnrs lowered HilleVax from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 9th. HC Wainwright reissued a “neutral” rating and issued a $2.00 price target on shares of HilleVax in a research note on Monday, August 12th. Finally, Guggenheim lowered shares of HilleVax from a “buy” rating to a “neutral” rating in a research note on Monday, July 8th. Six investment analysts have rated the stock with a hold rating, According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $9.20.

HilleVax Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.